Science

Yan Leyfman

Apr 17, 2025, 13:47

Yan Leyfman: CAR-T Cell Therapy and Gliomas

Yan Leyfman, Co-founder and executive director of MedNews Week, shared an article by Eric P. Grewal, et al. on LinkedIn:

“CAR T Cell Therapy & Gliomas: The Road Ahead.

CAR T cell therapy has transformed care for blood cancers—but bringing that success to malignant gliomas like GBM and DMG remains a major challenge.

Over the past decade, clinical trials targeting glioma-associated antigens such as:

IL-13Rα2, HER2, EGFR/EGFRvIII, EphA2, GD2, and B7-H3.

…have shown proof-of-concept, but hurdles like antigen escape and short-lived T cells remain.

What’s next?

Multi-antigen targeting.
Novel delivery routes.
Alternative cell sources.

These innovative approaches are pushing the boundaries of what’s possible in brain tumor immunotherapy. Continued evolution is key to unlocking durable responses and expanding the CAR T frontier.”

Clinical progress in the development of CAR T cells to treat malignant glioma.

Authors: Eric P. Grewal, et al.

Yan Leyfman: CAR-T Cell Therapy and Gliomas

B7-H3 blood cancers brain tumor immunotherapy cancer CAR T-cell therapy clinical trials EGFR/EGFRvIII EphA2 Eric P. Grewal fight against cancer GD2 gliomas Global fight against cancer HER2 IL-13Rα2 MedNews Week OncoDaily Oncology Yan Leyfman

Eric Abidal and Liver Cancer: How He Returned to Football After Overcoming Illness

April is Head and Neck Cancer Awareness Month

Is Cancer Hereditary? Myths and Facts about Cancer Genetics

Neuroendocrine Lung Tumors: Types, Symptoms, Diagnosis, Treatment and 2025 updates

Cancer Center Near Me: Dana-Farber Cancer Institute